Your browser is no longer supported. Please, upgrade your browser.
Settings
BTAI BioXcel Therapeutics, Inc. daily Stock Chart
BTAI [NASD]
BioXcel Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.03 Insider Own0.90% Shs Outstand17.73M Perf Week46.29%
Market Cap618.60M Forward P/E- EPS next Y-2.96 Insider Trans0.00% Shs Float8.32M Perf Month104.39%
Income-31.80M PEG- EPS next Q-0.63 Inst Own24.20% Short Float5.32% Perf Quarter441.77%
Sales- P/S- EPS this Y-355.80% Inst Trans3.80% Short Ratio0.94 Perf Half Y298.29%
Book/sh2.19 P/B15.93 EPS next Y-30.60% ROA-78.50% Target Price52.60 Perf Year332.88%
Cash/sh2.27 P/C15.35 EPS next 5Y- ROE-97.10% 52W Range3.76 - 43.63 Perf YTD138.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.03% Beta-
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low827.93% ATR4.00
Employees18 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)69.73 Volatility18.21% 12.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-83.30% Profit Margin- Rel Volume1.99 Prev Close34.20
ShortableYes LT Debt/Eq0.00 EarningsMar 05 BMO Payout- Avg Volume468.93K Price34.89
Recom1.80 SMA2054.03% SMA50115.89% SMA200230.01% Volume911,127 Change2.02%
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-12-19Initiated SunTrust Buy $24
Feb-20-20 07:30AM  BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -16.87%
Feb-19-20 04:54PM  BioXcel Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
07:21AM  The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga
Feb-18-20 07:00AM  BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501 GlobeNewswire +7.09%
Feb-07-20 07:00AM  BioXcel Therapeutics to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire
Feb-06-20 07:47AM  The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs Benzinga
Feb-05-20 07:00AM  BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms GlobeNewswire +15.16%
Jan-28-20 06:13PM  Get In on the AI Health Care Revolution With Globus, BioXcel, Apple, Amazon and Google GuruFocus.com
Jan-25-20 09:28AM  We're Keeping An Eye On BioXcel Therapeutics's (NASDAQ:BTAI) Cash Burn Rate Simply Wall St.
Jan-10-20 06:45AM  BTAI: Potentially Transformative Year Ahead for BioXcel Zacks Small Cap Research +16.15%
Jan-07-20 07:00AM  BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia GlobeNewswire
Dec-30-19 07:00AM  BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder GlobeNewswire
Dec-22-19 07:42PM  Hedge Funds Have Never Been This Bullish On BioXcel Therapeutics, Inc. (BTAI) Insider Monkey
Dec-11-19 07:00AM  BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types GlobeNewswire
Dec-06-19 06:40AM  BTAI: Pivotal Phase 3 Trials for BXCL501 to Initiate by End of 2019 Zacks Small Cap Research
Dec-03-19 07:00AM  BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA GlobeNewswire +7.93%
Nov-26-19 07:00AM  BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
07:00AM  BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-21-19 06:30AM  BTAI: Phase 3 Trials of BXCL501 in Agitation to Initiate Before Year End Zacks Small Cap Research
Nov-14-19 07:00AM  BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-07-19 07:00AM  BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast Business Wire
Oct-30-19 06:00AM  BTAI: Initiating Coverage of BioXcel Therapeutics, Inc.; AI Driven Drug Development Zacks Small Cap Research
Oct-27-19 09:51AM  How Many BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Oct-24-19 08:00AM  BioXcel Therapeutics to Present at the 26th Annual Prostate Cancer Foundation Scientific Retreat Business Wire
Oct-10-19 08:00AM  BioXcel Therapeutics Highlights Upcoming Major Milestones GlobeNewswire
Sep-26-19 09:11AM  BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -23.55%
Sep-25-19 04:27PM  BioXcel Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Sep-18-19 08:00AM  BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices GlobeNewswire
Sep-04-19 08:00AM  BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML) GlobeNewswire
Aug-20-19 08:00AM  BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defenses (DoD) Congressionally Directed Medical Research Programs (CDMRP) for Development of BXCL501 GlobeNewswire
Aug-06-19 07:30AM  BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-31-19 08:00AM  BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference GlobeNewswire
Jul-30-19 04:01PM  BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update GlobeNewswire
Jul-29-19 02:34PM  Is BioXcel Therapeutics (NASDAQ:BTAI) A Risky Investment? Simply Wall St.
Jul-26-19 12:21PM  BioXcel's CEO On BXCL501: 'This Is A Pretty Unique Drug' Benzinga
Jul-22-19 06:00AM  BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia GlobeNewswire
Jul-01-19 08:00AM  BioXcel Therapeutics Added to Russell 3000® Index GlobeNewswire
Jun-18-19 08:00AM  BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-10-19 08:00AM  BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial GlobeNewswire
Jun-06-19 08:00AM  BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs GlobeNewswire
Jun-03-19 08:00AM  BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for Lead Immuno-Oncology Program, BXCL701 GlobeNewswire
May-31-19 04:05PM  BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-28-19 11:02AM  BioXcel Therapeutics, Inc. uses AI technology to develop drugs Yahoo Finance Video
May-20-19 07:30AM  BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases GlobeNewswire
May-13-19 08:00AM  BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City GlobeNewswire -14.70%
May-09-19 08:00AM  BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference GlobeNewswire -8.31%
May-07-19 08:00AM  BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update GlobeNewswire
May-02-19 08:36AM  BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation GlobeNewswire
Apr-29-19 05:17PM  BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update GlobeNewswire +5.12%
11:08AM  Does BioXcel Therapeutics's (NASDAQ:BTAI) Share Price Gain of 46% Match Its Business Performance? Simply Wall St.
Apr-03-19 08:00AM  BioXcel Therapeutics to Present at Upcoming Investor Conferences in April GlobeNewswire +5.23%
Apr-01-19 08:03AM  BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting GlobeNewswire
Mar-25-19 08:00AM  BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC) GlobeNewswire
Mar-13-19 04:01PM  BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference GlobeNewswire
Mar-11-19 08:00AM  BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting GlobeNewswire +11.41%
Mar-07-19 08:00AM  BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update GlobeNewswire
Mar-05-19 04:01PM  BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March GlobeNewswire -5.04%
Mar-04-19 08:00AM  BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer GlobeNewswire
Mar-01-19 08:30AM  BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call GlobeNewswire
Feb-06-19 08:00AM  BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference GlobeNewswire +18.64%
Feb-04-19 08:00AM  BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal GlobeNewswire +10.60%
Jan-09-19 08:50AM  The Most Innovative Healthcare AI Developments of 2019 ACCESSWIRE
Jan-03-19 08:00AM  BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimers Disease GlobeNewswire +43.84%
Dec-28-18 04:55PM  BioXcel Surges on Fast Track Designation to Agitation Drug Zacks -9.63%
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE +80.91%
08:00AM  BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation GlobeNewswire
Dec-19-18 04:00AM  BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation GlobeNewswire -10.51%
Dec-12-18 08:07AM  The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel Benzinga
04:00AM  BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation GlobeNewswire
Dec-03-18 06:00AM  BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire +5.38%
Nov-21-18 07:40AM  Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-14-18 04:00AM  BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development GlobeNewswire
Nov-09-18 07:00AM  BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update GlobeNewswire
Nov-05-18 04:00AM  BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer GlobeNewswire -5.11%
Nov-02-18 06:00AM  BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call GlobeNewswire
Oct-31-18 04:00AM  BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting GlobeNewswire -5.93%
Oct-30-18 04:00AM  BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation GlobeNewswire +6.51%
Oct-11-18 04:01PM  BioXcel Therapeutics to Present at the 2018 BIO Investor Forum GlobeNewswire
Oct-08-18 07:00AM  BioXcel Therapeutics Announces Submission of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer GlobeNewswire -5.91%
Sep-24-18 07:00AM  BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer GlobeNewswire
Sep-18-18 08:00AM  BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs GlobeNewswire
Sep-04-18 08:00AM  BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations GlobeNewswire +7.39%
Aug-28-18 08:00AM  BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference GlobeNewswire
Aug-22-18 08:00AM  BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development GlobeNewswire
Aug-08-18 04:01PM  BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
02:30PM  BioXcel Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 07:02AM  BioXcel Therapeutics Strengthens Leadership Team with Industry Veteran Michael De Vivo Ph.D. as Vice President, Neuroscience GlobeNewswire
Aug-02-18 04:05PM  BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update GlobeNewswire +5.28%
08:00AM  BioXcel Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-31-18 08:00AM  BioXcel Therapeutics Enhances Leadership with Appointment of Vikas Sharma, Ph.D. as Vice President of Business Development GlobeNewswire +5.90%
Jul-30-18 02:47PM  7 Best Stocks to Buy to Upgrade Your AI Portfolio InvestorPlace
Jul-24-18 08:00AM  DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal GlobeNewswire -11.13%
Jul-10-18 08:00AM  BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501 GlobeNewswire +17.77%
Jul-03-18 02:31PM  7 Megatrend Stocks With Long-Term Upside Potential InvestorPlace
Jun-27-18 04:01PM  BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development GlobeNewswire
Jun-26-18 08:30AM  BioXcel Therapeutics Added to Russell Microcap® Index GlobeNewswire
Jun-14-18 01:41PM  5 AI Biotech Stocks to Bet On Now InvestorPlace
Jun-13-18 08:00AM  BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management GlobeNewswire
Jun-07-18 08:00AM  BioXcel Therapeutics Appoints Vincent J. ONeill M.D., as Senior Vice President and Chief Medical Officer GlobeNewswire
Jun-05-18 08:00AM  BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yocca FrankChief Scientific OfficerFeb 14Option Exercise0.4180,00032,80088,397Feb 19 05:22 PM